Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $49,625.40 in Stock

Posted by Scott Moore on Sep 17th, 2026

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Get Free Report) Director Ramiro Guerrero bought 37,595 shares of the stock in a transaction on Thursday, September 10th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $49,625.40. Following the acquisition, the director directly owned 773,296 shares of the company’s stock, valued at $1,020,750.72. The trade was a 5.11% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The shares were purchased at an average cost of $1.35 per share, with a total value of $62,937.00.
On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, for a total transaction of $108,752.21.
On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $12,414.09.
On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.33 per share, with a total value of $2,386.02.
On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Up 4.5%

Shares of MAIA opened at $1.40 on Thursday. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $3.19. The stock has a market cap of $85.16 million, a P/E ratio of -2.26 and a beta of 0.25. The company has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.37.

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, analysts forecast that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Trading of MAIA Biotechnology

A number of hedge funds have recently modified their holdings of MAIA. PVG Asset Management Corp acquired a new position in shares of MAIA Biotechnology during the 1st quarter worth about $46,000. Susquehanna International Group LLP acquired a new stake in MAIA Biotechnology in the 2nd quarter valued at about $51,000. Corsair Capital Management L.P. bought a new position in MAIA Biotechnology during the first quarter worth about $140,000. BlackRock Inc. acquired a new position in MAIA Biotechnology during the second quarter worth approximately $580,000. Finally, Cable Car Capital LP bought a new stake in MAIA Biotechnology in the second quarter valued at approximately $741,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research centers on telomeres, protective structures at the ends of chromosomes that are maintained in many cancer cells through telomerase activity.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine (6-thio-dG). The compound is designed to be activated in telomerase-positive cancer cells, promoting telomere dysfunction and DNA damage that may lead to cancer-cell death.